US2017100472A1PendingUtilityA1

Combination vaccines with serogroup b meningococcus and d/t/p

Assignee: GLAXOSMITHKLINE BIOLOGICALS SAPriority: Sep 6, 2012Filed: Dec 19, 2016Published: Apr 13, 2017
Est. expirySep 6, 2032(~6.1 yrs left)· nominal 20-yr term from priority
A61P 37/04A61K 2039/6037A61K 2039/55566A61K 39/39A61K 2039/55511A61K 39/095A61K 2039/55505A61K 2039/55572A61P 31/04
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 : An immunogenic composition, comprising: (a) a serogroup B meningococcus immunogen; and (b) a diphtheria toxoid, a tetanus toxoid, and a pertussis toxoid, wherein the diphtheria toxoid is present in an excess relative to tetanus toxoid as measured in Lf units. 
     
     
         2 : The composition of  claim 1 , further comprising an adjuvant.

Join the waitlist — get patent alerts

Track US2017100472A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.